Skip to main
MLYS

MLYS Stock Forecast & Price Target

MLYS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Mineralys Therapeutics has established a compelling case for its product candidate, lorundrostat, which has shown a significant placebo-adjusted blood pressure reduction exceeding 10mmHg, garnering positive attention from prescribers. The product's robust profile in treating uncontrolled and resistant hypertension positions it favorably against competitors, particularly in the context of the positive data from the Advance-HTN trial. Anticipated feedback from the FDA and an upcoming New Drug Application (NDA) submission further strengthen the outlook for lorundrostat and the company’s potential market presence.

Bears say

Mineralys Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, particularly related to its developmental candidate, lorundrostat. Key concerns include the potential failure to meet peak commercial revenue estimates due to challenges in market size and penetration rates, alongside pricing issues. Furthermore, there are substantial uncertainties regarding the company's ability to secure necessary capital for ongoing operations and the future of its program development and commercialization efforts.

MLYS has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mineralys Therapeutics Inc (MLYS) Forecast

Analysts have given MLYS a Buy based on their latest research and market trends.

According to 6 analysts, MLYS has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mineralys Therapeutics Inc (MLYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.